KBC Group NV Acquires 1,092 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

KBC Group NV grew its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 30.5% in the third quarter, Holdings Channel reports. The fund owned 4,675 shares of the biopharmaceutical company’s stock after acquiring an additional 1,092 shares during the quarter. KBC Group NV’s holdings in TG Therapeutics were worth $109,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. NBC Securities Inc. raised its holdings in TG Therapeutics by 58.9% during the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 485 shares during the period. Ashton Thomas Private Wealth LLC bought a new position in shares of TG Therapeutics during the second quarter valued at about $35,000. Blue Trust Inc. grew its position in shares of TG Therapeutics by 127.3% in the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 849 shares during the last quarter. ORG Wealth Partners LLC bought a new position in TG Therapeutics in the 3rd quarter worth $53,000. Finally, DekaBank Deutsche Girozentrale purchased a new stake in TG Therapeutics in the first quarter worth about $58,000. 58.58% of the stock is owned by institutional investors.

TG Therapeutics Trading Up 11.5 %

Shares of TG Therapeutics stock opened at $34.74 on Friday. The company has a fifty day moving average of $25.39 and a 200 day moving average of $21.51. TG Therapeutics, Inc. has a fifty-two week low of $12.26 and a fifty-two week high of $36.50. The company has a market capitalization of $5.41 billion, a P/E ratio of -347.37 and a beta of 2.19. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $83.90 million during the quarter, compared to analysts’ expectations of $81.68 million. During the same period last year, the firm posted $0.73 EPS. TG Therapeutics’s quarterly revenue was down 49.4% compared to the same quarter last year. On average, sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.17 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on TGTX. B. Riley boosted their target price on shares of TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. The Goldman Sachs Group increased their price objective on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. HC Wainwright boosted their target price on shares of TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Finally, TD Cowen initiated coverage on shares of TG Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $37.67.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, Director Sagar Lonial sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $30.44, for a total transaction of $152,200.00. Following the sale, the director now directly owns 100,195 shares in the company, valued at $3,049,935.80. This represents a 4.75 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. 10.50% of the stock is currently owned by company insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.